A new combination vaccine for measles, mumps, rubella and varicella
- PMID: 16801995
- DOI: 10.1358/dot.2006.42.5.973586
A new combination vaccine for measles, mumps, rubella and varicella
Abstract
ProQuad is a recently approved combination vaccine for simultaneous vaccination against measles, mumps, rubella and varicella in children aged 12 months to 12 years. It combines two well-established vaccines: Measles, Mumps, Rubella Virus Vaccine Live (M-M-R II) and Varicella Virus Vaccine Live (Varivax with higher varicella-zoster titer). Whereas vaccination against measles, mumps and rubella has almost 100% coverage, vaccination against varicella shows a significantly lower uptake of approximately 84%. Clinical studies on the immunogenicity and efficacy of ProQuad demonstrated seroconversion rates and a magnitude of antibody response similar to those observed after administration of its individual components, M-M-R II and Varivax vaccines. The incidence of local side effects (pain/tenderness/soreness, erythema, swelling, ecchymosis and rash) and systemic adverse effects (fever, irritability, rash, upper respiratory infection, viral exanthema and diarrhea) is similar to or lower than that observed in component vaccines. ProQuad is a highly immunogenic combination vaccine with a good safety profile. The use of ProQuad combination vaccine will simplify immunization delivery by providing protection against more diseases with fewer injections and less pain, improve timely vaccination coverage and reduce the health-care costs for additional health visits. The ProQuad combination vaccine facilitates implementation of varicella vaccination into routine childhood immunization schedules and will help to protect children against these four potentially serious diseases.
Similar articles
-
Measles-mumps-rubella-varicella combination vaccine (ProQuad): a guide to its use in children in the E.U.Paediatr Drugs. 2015 Apr;17(2):167-74. doi: 10.1007/s40272-015-0123-7. Paediatr Drugs. 2015. PMID: 25732634
-
Use of combination measles, mumps, rubella, and varicella vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP).MMWR Recomm Rep. 2010 May 7;59(RR-3):1-12. MMWR Recomm Rep. 2010. PMID: 20448530
-
A combination vaccine against measles, mumps, rubella and varicella.Drugs Today (Barc). 2008 Apr;44(4):279-92. doi: 10.1358/dot.2008.44.4.1210755. Drugs Today (Barc). 2008. PMID: 18536786 Review.
-
Varicella vaccines and measles, mumps, rubella, and varicella vaccine.J Pediatr (Rio J). 2006 Jul;82(3 Suppl):S101-8. doi: 10.2223/JPED.1496. J Pediatr (Rio J). 2006. PMID: 16826308 Review.
-
A combination measles, mumps, rubella, and varicella vaccine (ProQuad) given to 4- to 6-year-old healthy children vaccinated previously with M-M-RII and Varivax.Pediatrics. 2006 Feb;117(2):265-72. doi: 10.1542/peds.2005-0092. Pediatrics. 2006. PMID: 16452343 Clinical Trial.
Cited by
-
Exploring novel and potent cell penetrating peptides in the proteome of SARS-COV-2 using bioinformatics approaches.PLoS One. 2021 Feb 19;16(2):e0247396. doi: 10.1371/journal.pone.0247396. eCollection 2021. PLoS One. 2021. PMID: 33606823 Free PMC article.
-
Combination Measles-Mumps-Rubella-Varicella Vaccine in Healthy Children: A Systematic Review and Meta-analysis of Immunogenicity and Safety.Medicine (Baltimore). 2015 Nov;94(44):e1721. doi: 10.1097/MD.0000000000001721. Medicine (Baltimore). 2015. PMID: 26554769 Free PMC article. Review.
-
The bacterial second messenger cdiGMP exhibits promising activity as a mucosal adjuvant.Clin Vaccine Immunol. 2007 Aug;14(8):952-8. doi: 10.1128/CVI.00119-07. Epub 2007 Jun 13. Clin Vaccine Immunol. 2007. PMID: 17567766 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
